ScoreWhy is Astrazeneca Pharma India Ltd ?
1
High Management Efficiency with a high ROE of 21.62%
2
Company has a low Debt to Equity ratio (avg) at 0 times
3
The company has declared Positive results for the last 4 consecutive quarters
- OPERATING CF(Y) Highest at Rs 65.36 Cr
- DPS(Y) Highest at Rs 32.00
- PAT(Latest six months) At Rs 114.26 cr has Grown at 35.70%
4
With ROE of 29.1, it has a Very Expensive valuation with a 28.4 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 36.58%, its profits have risen by 66.5% ; the PEG ratio of the company is 1.5
5
Majority shareholders : Promoters
6
Consistent Returns over the last 3 years
- Along with generating 36.58% returns in the last 1 year, the stock has outperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Astrazeneca Phar for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Astrazeneca Phar
-3.75%
1.03
35.48%
Sensex
-4.3%
0.43
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
22.23%
EBIT Growth (5y)
22.08%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
1.88
Tax Ratio
26.29%
Dividend Payout Ratio
69.12%
Pledged Shares
0
Institutional Holding
8.27%
ROCE (avg)
97.56%
ROE (avg)
21.62%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
94
Industry P/E
31
Price to Book Value
24.41
EV to EBIT
77.53
EV to EBITDA
66.56
EV to Capital Employed
44.10
EV to Sales
8.79
PEG Ratio
5.76
Dividend Yield
0.41%
ROCE (Latest)
63.10%
ROE (Latest)
26.07%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
ROCE(HY)
Highest at 37.81%
NET SALES(Q)
Highest at Rs 611.57 cr
-11What is not working for the Company
PAT(Q)
At Rs 31.55 cr has Fallen at -45.6% (vs previous 4Q average
CASH AND CASH EQUIVALENTS(HY)
Lowest at Rs 399.94 cr
PBDIT(Q)
Lowest at Rs 44.83 cr.
OPERATING PROFIT TO NET SALES (Q)
Lowest at 7.33%
PBT LESS OI(Q)
Lowest at Rs 39.93 cr.
Loading Valuation Snapshot...
Here's what is working for Astrazeneca Phar
Net Sales - Quarterly
Highest at Rs 611.57 cr and Grown
each quarter in the last five quartersMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Net Sales - Quarterly
At Rs 611.57 cr has Grown at 21.9% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 501.54 CrMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Here's what is not working for Astrazeneca Phar
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 39.93 cr has Fallen at -41.1% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 67.84 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 31.55 cr has Fallen at -45.6% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 58.05 CrMOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Lowest at Rs 44.83 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Lowest at 7.33%
in the last five quartersMOJO Watch
Company's efficiency has deteriorated
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Lowest at Rs 39.93 cr.
in the last five quartersMOJO Watch
Near term PBT trend is negative
PBT less Other Income (Rs Cr)
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 399.94 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
